H.C. Wainwright initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $10 price target Perspective is a clinical-stage ...

H.C. Wainwright analyst Scott Buck lowered the firm’s price target on AudioEye (AEYE) to $22 from $37 and keeps a Buy rating on the shares post ...

Shares of Core Scientific Inc. (CORZ) gained almost 8% in Tuesday’s regular session and extended gains during after-hours ...

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...

UroGen Pharma (NASDAQ:URGN – Get Free Report) had its price target decreased by equities researchers at HC Wainwright from ...

Investment analysts at HC Wainwright cut their FY2028 earnings per share (EPS) estimates for Oncolytics Biotech in a research ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. initiated coverage of Inuvo (NYSEAM:INUV) with a Buy ...

H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of ...

Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...

Fintel reports that on March 5, 2025, HC Wainwright & Co. initiated coverage of Intellia Therapeutics (LSE:0JBU) with a Buy recommendation. There are 572 funds or institutions reporting positions ...

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com. IN8bio is a clinical-stage ...